High AnxA1 expression levels have been found in breast cancer [167,168], melanomas [169], hepatocellular carcinomas [170], colorectal cancers [171], gliomas [172], lung adenocarcinomas [173,174] and prostate cancer [175], correlating with worse prognosis, lower disease-free survival rates and lower overall survival [170,174,176]. Here, ANXA1 is linked to hepatocellular carcinoma.